Study Contests Savings From Pay-For-Delay Bill

Law360, New York (August 12, 2010, 6:17 PM EDT) -- The Congressional Budget Office has “significantly overstated” the billions of dollars in potential savings it said would result from proposed legislation banning pay-for-delay settlements between brand-name and generic-drug companies, according to a study.

Funded by the Pharmaceutical Research and Manufacturers of America and released Tuesday, the economic analysis of the pay-for-delay measure restricting generic-drug companies from accepting money to resolve patent litigation found that the CBO’s methodology and an earlier study by the Federal Trade Commission wrongly concluded that outlawing reverse payments would expedite generic entry...
To view the full article, register now.